Surrogate Markers as Measures of Efficacy: Limitations & Complexities

Criteria for Study Endpoints

- Sensitive to Treatment Effects Eg: Analgesic in terminally ill - Pain Relief, not Survival
- Clinically Relevant
- -Screening Evaluation: Biological Activity
 - Viral load
 - Immunophenotypic
 - Immunofunctional markers

- -Definitive Evaluation: Clinical Efficacy
 - Survival duration
 - Symptomatic events
 - Functional status

Obtaining Definitive Evidence of Clinical Efficacy

- Treatment effects on Surrogate Endpoint
 - Establish biological activity
 - Do not establish clinical efficacy

Time

Disease

Surrogate True Clinica Endpoint Outcome






Illustration:

Chronic Granulomatous Disease

- CDG → Recurrent Serious Infections
- Gamma-INF ... Increase Bacterial Killing and Superoxide Production?
- International CDG Study Group Trial Gamma-INF:
 - 70% Reduction in
 - **Recurrent Serious Infections**
 - Essentially No Effect on Biological Markers

Time





Pooled Analysis of Immediate vs. Deferred AZT

Year of	No. AIDS/Death		
	Events	vents <u>Hazard Ratio</u>	
<u>Follow-up</u> 0-	209	0.52	(0.39 - 0.68)
0- 1-	357	0.94	(0.76 - 1.16)
1- 2-	440	1.05	(0.87 - 1.27)
3-	369	1.12	(0.91 - 1.38)
<u> </u>	307	0.98	(0.78 - 1.23)
5+	226	1.10	(0.84 - 1.43)

*Immediate vs. deferred AZT

Large Randomized Trials with Long-Term Follow-up are Needed

- Short-term trials cannot address long-term risks and benefits
- Small studies cannot reliably assess treatment differences in clinical outcomes

Clinical Endpoint Trial

HIV+ Patients CD4 + < 300 $CD4 + \ge 300$ $\mathbb{R} < ART + Immune Based R_x$ (750) (2000) (750) (2000)

5 years follow-up

Outcome: Progression to AIDS/Death Survival

How does one validate a surrogate endpoint?

Prentice's Sufficient Condition

1. The surrogate endpoint must be correlated with the clinical outcome

 The surrogate endpoint must fully capture the net effect of the treatm on the clinical outcon $Z = 1 : \text{Control} ; \quad Z = 0 : \text{Treatment}$ S(t) : Surrogate Endpoint at t $\lambda(t \mid Z) = \lambda_0(t) e^{\alpha Z} \qquad (1)$ $\lambda(t \mid Z, S(t)) = \lambda_0(t) e^{\beta Z + \gamma S(t)} \qquad (2)$

Proportion of treatment effect explained by the surrogate endpoint:

 $p=1-\frac{\beta}{\alpha}$

Meta-analyses are required to explore the validity of surrogate endpoints

Validation of Surrogate Endpoir

Statistical

Meta-analyses of clinical trials data

Clinical

Comprehensive understanding of the

 Causal pathways of the disease proc
 Intervention's intended and uninten mechanisms of action

Surrogate Markers -Another Significant Limitation

Even if, for treatment Z, S is a valid Surrogate Marker for T, it may not be for treatment Z* if Z and Z* have differing mechanisms of action

Example

S - CD-4 LevelsZ - Neucleoside AnaloguT - AIDS / DeathZ* - Vaccines for Early R

Use of Surrogate Marke

In Screening Trials... Primary Endpoints

In Definitive Trials... Supportive Data on Mechanism of Acti